EGFR and colorectal carcinoma: Detected in 40% of CRC, KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations in codons 12 or 13 induce constitutive activation, inducing RAS/RAF/MAPK pathways, causing worse prognosis and high resistance to EGFR-targeted therapies [9].